AbbVie Inc (ABBV)vsCollegium Pharmaceutical Inc (COLL)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
COLL
Collegium Pharmaceutical Inc
$37.80
-3.89%
HEALTHCARE · Cap: $1.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 7948% more annual revenue ($62.82B vs $780.57M). COLL leads profitability with a 8.1% profit margin vs 5.8%. COLL trades at a lower P/E of 19.8x. COLL earns a higher WallStSmart Score of 65/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
COLL
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-20.5%
Fair Value
$168.19
Current Price
$201.55
$33.36 premium
Margin of Safety
+89.2%
Fair Value
$416.48
Current Price
$37.80
$378.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Strong operational efficiency at 30.0%
Every $100 of equity generates 24 in profit
Earnings expanding 31.5% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : COLL
The strongest argument for COLL centers on Operating Margin, Return on Equity, EPS Growth. Revenue growth of 12.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : COLL
The primary concerns for COLL are Market Cap.
Key Dynamics to Monitor
COLL carries more volatility with a beta of 0.76 — expect wider price swings.
COLL is growing revenue faster at 12.9% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
COLL scores higher overall (65/100 vs 63/100) and 12.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?